RxDoctor Payments DataLook up a doctor →

Walford Lindo, MD

Family Medicine · Brooklyn, NYNPI 1972677516

Payments from drug & device makers

$104,161in general payments, 2019–2025

Across 627 payments — averaging $166.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$86K
  • Amgen$12K
  • AstraZeneca$1K
  • Amarin Pharma, Inc.$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$575
  • plus $3K from 24 others

What the payments were for

  • Speaking & faculty fees$82,78279%
  • Travel & lodging$5,5825%
  • Food & beverage$15,77215%
  • Education$260%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$104,161 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$67,834
Medicare patients
66
Services billed
1,618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VascepaIcosapent Ethyl290$205,598
OzempicSemaglutide119$133,636
JardianceEmpagliflozin84$119,696
FarxigaDapagliflozin Propanediol100$100,757
RybelsusSemaglutide43$75,314
EntrestoSacubitril/Valsartan83$73,831
EliquisApixaban38$59,211
Tresiba Flextouch U-200Insulin Degludec82$53,215
ProliaDenosumab30$52,502
XareltoRivaroxaban58$44,866
JanuviaSitagliptin Phosphate37$37,618
TradjentaLinagliptin22$29,181
Repatha SureclickEvolocumab25$19,507
LinzessLinaclotide27$16,933
JanumetSitagliptin Phos/Metformin Hcl16$14,957

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$85,694$208,950162 claims
Boehringer IngelheimJardiance, Tradjenta$575$148,878106 claims
AstraZenecaFarxiga, Symbicort$1,264$104,066112 claims
NovartisEntresto$183$73,83183 claims
PfizerEliquis$176$59,21138 claims
MerckJanuvia, Janumet$139$52,57553 claims
AmgenProlia$11,679$52,50230 claims
Johnson & JohnsonXarelto$215$44,86658 claims
AbbVieLinzess, Synthroid$155$19,12143 claims
GSKBreo Ellipta$306$5,56814 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →